Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|September 4, 2024

Promising Therapy Approaches for Advanced Friedreich Ataxia

A key opinion leader explores new and promising treatment approaches for managing advanced stages of Friedreich ataxia.

Episodes in this series

This series features 1 kol.

EP. 1 Friedreich Ataxia: Addressing Treatment Objectives and Comorbidities

This series features 1 kol.

EP. 2 Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy

This series features 1 kol.

EP. 3 Engaging mFARS Scale to Monitor Friedreich Ataxia Progression

This series features 1 kol.

EP. 4 Managing Adverse Events in Novel Friedreich’s Ataxia Therapy

This series features 1 kol.

EP. 5 Examining Trial Data on Omaveloxolone Efficacy

This series features 1 kol.

EP. 6 Promising Therapy Approaches for Advanced Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 7 Friedreich Ataxia: Looking Forward at the Treatment Landscape

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 8 Epidemiology, Pathophysiology, and Symptomatology of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 9 Diagnosis of Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 10 Impact of Friedreich Ataxia on Quality of Life

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 11 Clinical Utility of the Modified Friedreich Ataxia Rating Scale

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 12 Comorbidities and Complications Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 13 Challenges Associated With Friedreich Ataxia

Susan Perlman, MD, an expert on Friedreich's ataxia

EP. 14 Future Considerations for Friedreich Ataxia

Video content above is prompted by the following:

In your opinion, what are the most promising emerging therapeutic avenues for managing advanced stages of FA, and how do you see them impacting clinical practice in the future?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

ENERGY Trial Shows Early Fatigue Benefit With Nipocalimab in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 26th 2026

CRC animation | Image Credit: Thipphaphone - stock.adobe.com

Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates

ByBrooke McCormick

June 26th 2026

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

HR-Positive Breast Cancer: Clinical Use of Oral SERDs in Combination vs Monotherapy

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

HR-Positive Breast Cancer: Evolving Role of ESR1 Mutations in Endocrine Resistance

ByAdam Brufsky, MD, PhD,Hope Rugo, MD,Dr. Mabel Mardones, MD,Ms. Lori Brisbin, MS, MLS Healthcare Law,Dr. Lisa Raff, PharmD

Published: June 26th 2026 | Updated: June 26th 2026

Stamp that says "FDA Approved" in blue ink. | Image Credit: Surendra - stock.adobe.com

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

ByElla Hohmann, MS

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers

Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma

Health Equity & Access Weekly Roundup: June 26, 2026

ATTR-CM Incidence, Prevalence Rose Sharply in the US